Bedside Clinical Systems featured on Research Innovation and Commercialization Centre (RICC) panel discussion In an article for YourMississaugaBiz.com, Jon Cook writes, " 'The health-care industry is relying more on the…
TORONTO, Canada (April 24, 2013) — Flybits Inc. announced today that Forrester Research Inc. has recognized Flybits, a Toronto-based start-up company, as a tool for on-demand marketing processes in a recent report.
The February 2013 Forrester report, written by Anthony Mullen, “Emerging Touchpoints Require a Marketing Mind Shift,” states that to master the new basics, marketing professionals must increase corporate spending on innovation and formalize working relationships in areas such as customer experience, analytics, IT and product design — all of which the Flybits framework addresses.
To address the problem of information overload on mobile devices, Flybits unifies the mobile user experience across multiple channels, creating a cohesive mobile presence for a company’s communication needs. Rather than introducing heterogeneous mobile channels to users, all relevant information can be structured within Flybits Zones — semantic-driven, rule-oriented geo-fences.
WATERLOO, ON, Canada (April 23, 2013) — ClevrU Corporation today announced that it has acquired NewMindsets Inc., a company founded on online pedagogy researched and developed by two Schulich School of Business professors that has provided leading-edge educational content and services to over 10,000 Schulich students at York University over the past decade.
Through the acquisition, ClevrU will fully integrate NewMindsets’ proven e-teaching pedagogy in leadership, researched and developed by Professors Gareth Morgan and Jean Adams, into its world-class e-teaching platform, to be presented to York as a pilot and then delivered to millions of students worldwide.
TechVibes, EdSurge, Private Equity Hub, Yonge Street Media, and the Waterloo Record covered this announcement. The release is also viewable on CNW and in Chinese (.pdf).
The two companies announced a partnership in October 2012 to establish a second-generation online learning standard.
TORONTO, April 22, 2013 — MaRS Innovation, a Centre of Excellence for Commercialization and Research, today announced the formation of a strategic partnership with Pfizer Inc. to advance early-stage technologies related to human health in therapeutics and diagnostics.
Through this collaboration, MaRS Innovation and Pfizer will jointly identify investment opportunities emerging from well-validated scientific research discoveries within MaRS Innovation’s 16 member institutions, including the University of Toronto and its nine affiliated teaching hospitals.
“There’s growing consensus that transferring technologies from the university lab bench and into the market requires unique public-private partnerships,” said Dr. Raphael Hofstein, president and CEO of MaRS Innovation. “Partnering with MaRS Innovation gives Pfizer access to Toronto’s robust innovation pipeline and a close look at emerging IP from Canada. It signals both the strength and attractiveness of our commercialization model and Toronto-based research technologies to global industry players.”
“Our government is committed to making Ontario the best place to translate great ideas into innovative products that will gain demand around the world,” said the Honourable Reza Moridi, Ontario Minister of Research and Innovation. “Today’s announcement from MaRS Innovation is an exciting collaboration with Pfizer that will both advance healthcare technologies for Ontarians and help to strengthen our economy.”
CHICAGO, Illinois – April 22, 2013 – Merck Canada will be announcing today at the BIO International Convention that it is reinforcing its commitment to the Canadian life sciences research innovation sector.
Merck will provide $4 million in funding to the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) for future corridor projects developed in collaboration with two other Canadian Centres of Excellence for Commercialization and Research (CECRs) based in Ontario and in British Columbia.
This partnership announcement was covered by PEHub.
IRICoR will work in conjunction with MaRS Innovation and the Centre for Drug Research and Development (CDRD) to identify, develop and commercialize technologies in healthcare. All three CECR institutions – identified as CECR in 2008 by the federal government – share a common objective: facilitating and accelerating the commercialization of research breakthroughs that will improve the quality of life of Canadians and others around the world.
Over 9,600 people funded Toronto start-up’s one-dimensional mobile keyboard
TORONTO, Canada (April 18, 2013) — The Indiegogo campaign for Minuum, “the little keyboard for big fingers,” created by Whirlscape Inc., has closed after raising $87,369 in one month.
Minuum is a one-dimensional, tiny keyboard that frees up mobile screen space while allowing fast, accurate typing. Its specialized, patent-protected auto-correction algorithm allows highly imprecise typing, configuring the difference between what you type and what you mean in real time and getting it right even if you miss every single letter.
Read about the Minuum launch and reaching its $60,000 stretch milestone in previous posts. The posts include links to Minuum’s international media coverage. Most recently, their technology and Indiegogo success were featured in The Verge, the Financial Post, Mobile Syrup (includes an excellent Youtube interview with founder Will Walmsley, embedded below) and Tech2.
The campaign’s initial goal — $10,000 to fund the launch of an Android keyboard app — was reached within 14 hours. Since its launch on March 18, the campaign video has been viewed over 1.1 million times.
Did you know Minuum’s campaign is in Indiegogo’s top 10 of all time for projects with the largest number of supporters?
Stem Cell Therapeutics Corp. (TSX-V: SSS), a biopharmaceutical company developing cancer stem cell-related technologies, has signed a definitive license agreement with University Health Network (UHN), Toronto, Canada.
The agreement, developed in collaboration with MaRS Innovation, provides Stem Cell Therapeutics (SCT) with exclusive worldwide rights to an innovative clinical cancer stem cell program.
This announcement builds upon the existing stem cell program agreement between MI, Stem Cell Therapeutics and UHN, which was announced in November 2012.
The initial consideration of $1.6 million for the UHN License is to be satisfied by the issuance of 5,028,571 SCT common shares and 1,600,000 SCT common share purchase warrants to UHN and MaRS Innovation, each warrant allowing its holder to acquire one additional common share at an exercise price of $0.40 until March 15, 2018.
Dr. Kamran Khan, founder of BioDiaspora and an infectious disease physician and scientist at St. Michael’s Hospital, is among the experts studying the emergence of the H7N9 bird flu outbreak in China and the new coronavirus in the Middle East and Europe.
Global News National also covered this story on April 11, 2013. Watch Beatrice Politi and Carmen Chai‘s report, “Canadian scientists pioneer new formula in airport disease screening,” on the Global website.
The Toronto Star featured Khan’s research and BioDiaspora following the publication of his new paper in the Bulletin of the World Health Organization which assessed the impact of airport screenings in containing the 2009 H1N1 outbreak in Mexico.
Khan’s findings were covered in “Airport disease screening rarely worthwhile, Toronto study says,” by Helen Branswell.
Dr. Kamran Khan, founder of BioDiaspora and an infectious disease physician and scientist at St. Michael’s Hospital, is among the experts studying the emergence of the H7N9 bird flu outbreak in China.
Jennifer Yang interviewed Khan in today’s Toronto Star about the likelihood of the disease being easily transmitted from human to human or arriving in Canada, as SARS did in 2003.
Here’s an excerpt:
“This isn’t necessarily an event that poses a significant risk to Canada, at least based on all the current knowledge,” said Dr. Kamran Khan, an infectious disease specialist at St. Michael’s Hospital and founder of BioDiaspora, a program that predicts the potential spread of outbreaks. “Even if a case were to find its way into Canada, the likelihood of it spreading locally is quite low.”
BioDiaspora collects data on everything from air travel and weather to global distribution of disease-carrying insects and uses this data to forecast the potential spread of new diseases.
It has already performed a risk analysis of H7N9 for the U.S. Centers for Disease Control and Prevention, which contacted Khan last Tuesday for help.
Health risk to Canadians is currently low
Dr. Kamran Khan, founder of BioDiaspora and an infectious disease physician and scientist at St. Michael’s Hospital, is among the experts studying the emergence of the coronavirus.
Carolyn Brown interviewed Khan for a recent CMAJ article on the viral outbreak, “New coronavirus with ‘pandemic potential’ sparks global surveillance efforts.”
Schwartz Reisman Innovation Campus, West Tower
108 College Street, Suite 530
Toronto, ON M5G 0C6
info@tiap.ca